Open AccessLiraglutide (Saxenda)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.155
Subject(s) - medicine , diabetes mellitus , osteoarthritis , obesity , sleep apnea , weight loss , liraglutide , placebo , physical therapy , intensive care medicine , type 2 diabetes , alternative medicine , endocrinology , pathology
CADTH recommends that Saxenda should not be reimbursed by public drug plans for chronic weight management in adult patients.
Evidence from 3 studies demonstrated that Saxenda was associated with statistically significant reductions in body weight compared with placebo after 56 weeks of treatment.
No conclusions could be drawn about long-term benefits, particularly for clinically meaningful improvements in comorbidities identified as priorities by patients, such as diabetes, sleep apnea, osteoarthritis, and cardiovascular complications.
Patients identified a need for treatments that can improve potential obesity-related comorbidities, such as diabetes, sleep apnea, osteoarthritis, and cardiovascular complications. It is not clear whether Saxenda meets these needs.